Literature DB >> 10657698

Differential response of ventral midbrain and striatal progenitor cells to lesions of the nigrostriatal dopaminergic projection.

J N Kay1, M Blum.   

Abstract

In response to injury, progenitor cells in the adult brain can proliferate and generate new neurons and/or glia, which may then participate in injury-induced compensatory processes. In this study, we explore the ability of young adult mice to generate new cells in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesions, which selectively kill nigrostriatal dopaminergic neurons. Using the thymidine analogue 5-bromo-2'-deoxyuridine (BrdU), we labeled dividing cells 3, 10, and 15 days after MPTP lesion. A robust proliferative response was seen specifically in the substantia nigra (SN) and the dorsal striatum 3 days postlesion; the response persisted 10-14 days. To explore the fate of proliferative cells, we administered BrdU 3 days postlesion and examined the phenotype of BrdU(+) cells at various times thereafter, using double immunolabeling. In the striatum, nearly all newly-generated cells rapidly differentiated into GFAP(+) astrocytes that participated in the injury-induced glial reaction. In the SN, however, reactive astroglia were not BrdU(+). Some midbrain cells co-immunostained for BrdU and Mac-1, a microglial marker. However, most BrdU(+) cells in the SN failed to express markers for microglia, astroglia, oligodendroglia, or neurons, suggesting that they may remain as uncommitted progenitors. Thus, progenitors in the vicinity of the degenerating dopaminergic cell bodies respond differently to lesion than progenitors in the vicinity of the degenerating axon terminal. Although the putative midbrain progenitors appear uncommitted 22 days after their birth, it is possible that they may adopt neural or glial fates if allowed to survive longer, or if exposed to exogenous factors. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10657698     DOI: 10.1159/000017427

Source DB:  PubMed          Journal:  Dev Neurosci        ISSN: 0378-5866            Impact factor:   2.984


  20 in total

1.  No evidence for new dopaminergic neurons in the adult mammalian substantia nigra.

Authors:  Helena Frielingsdorf; Katherine Schwarz; Patrik Brundin; Paul Mohapel
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-21       Impact factor: 11.205

2.  Fibroblast growth factor 2 enhances striatal and nigral neurogenesis in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

Authors:  J Peng; L Xie; K Jin; D A Greenberg; J K Andersen
Journal:  Neuroscience       Date:  2008-03-07       Impact factor: 3.590

3.  Enhanced de novo neurogenesis and dopaminergic neurogenesis in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease-like mice.

Authors:  Xiaoyang Shan; Liying Chi; Michael Bishop; Chun Luo; Lindsey Lien; Zheng Zhang; Rugao Liu
Journal:  Stem Cells       Date:  2006-01-19       Impact factor: 6.277

4.  Post-MPTP treatment with granulocyte colony-stimulating factor improves nigrostriatal function in the mouse model of Parkinson's disease.

Authors:  Mark McCollum; Zhiyuan Ma; Eric Cohen; Rebecca Leon; Rui Tao; Jang-Yen Wu; Dipnarine Maharaj; Jianning Wei
Journal:  Mol Neurobiol       Date:  2010-04-21       Impact factor: 5.590

5.  Mutant α-synuclein and aging reduce neurogenesis in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

Authors:  Jun Peng; Julie K Andersen
Journal:  Aging Cell       Date:  2010-12-29       Impact factor: 9.304

6.  Paeoniflorin attenuates neuroinflammation and dopaminergic neurodegeneration in the MPTP model of Parkinson's disease by activation of adenosine A1 receptor.

Authors:  Hua-Qing Liu; Wei-Yu Zhang; Xue-Ting Luo; Yang Ye; Xing-Zu Zhu
Journal:  Br J Pharmacol       Date:  2006-06       Impact factor: 8.739

7.  Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30.

Authors:  Shunit Gal; Hailin Zheng; Mati Fridkin; Moussa B H Youdim
Journal:  Neurotox Res       Date:  2009-07-16       Impact factor: 3.911

8.  Methamphetamine induces low levels of neurogenesis in striatal neuron subpopulations and differential motor performance.

Authors:  I K Tulloch; L Afanador; L Baker; D Ordonez; H Payne; I Mexhitaj; E Olivares; A Chowdhury; J A Angulo
Journal:  Neurotox Res       Date:  2014-02-19       Impact factor: 3.911

Review 9.  Towards a Better Treatment Option for Parkinson's Disease: A Review of Adult Neurogenesis.

Authors:  Parisa Farzanehfar
Journal:  Neurochem Res       Date:  2016-09-10       Impact factor: 3.996

10.  1,25-dyhydroxyvitamin D3 attenuates L-DOPA-induced neurotoxicity in neural stem cells.

Authors:  Wooyoung Jang; Hyun-Hee Park; Kyu-Yong Lee; Young Joo Lee; Hee-Tae Kim; Seong-Ho Koh
Journal:  Mol Neurobiol       Date:  2014-08-08       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.